Abstract
A public–private partnership to establish biomarkers of dementia in Down's syndrome could aid the development of preventive therapies for the dementia associated with both Down's syndrome and Alzheimer's disease, based on the apparent common pathogenic role of amyloid precursor protein in the two conditions.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
Scientific Reports Open Access 03 April 2017
-
Advances in Alzheimer’s Disease Drug Development
BMC Medicine Open Access 25 March 2015
-
Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies
Current Neurology and Neuroscience Reports Open Access 14 September 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99 (2012).
Zigman, W., Silverman, W. & Wisniewski, H. M. Aging and Alzheimer's disease in Down syndrome: clinical and pathological changes. Mental Retard. Dev. Disabilities Res. Rev. 2, 73–79 (1996).
Zigman, W. B. & Lott, I. T. Alzheimer's disease in Down syndrome: neurobiology and risk. Mental Retard. Dev. Disabilities Res. Rev. 13, 237–246 (2007).
Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra29 (2012).
Barker, A. D. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97–100 (2009).
Acknowledgements
W. P. Battisti (Janssen Research & Development, USA) provided administrative and editorial support for this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Seth Ness, Michael Krams and Husseini Manji are full-time employees of Johnson & Johnson.
Rights and permissions
About this article
Cite this article
Ness, S., Rafii, M., Aisen, P. et al. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov 11, 655–656 (2012). https://doi.org/10.1038/nrd3822
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3822
This article is cited by
-
Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
Scientific Reports (2017)
-
Advances in Alzheimer’s Disease Drug Development
BMC Medicine (2015)
-
Genetic variants conferring susceptibility to Alzheimer’s disease in the general population; do they also predispose to dementia in Down’s syndrome
BMC Research Notes (2014)
-
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Alzheimer's Research & Therapy (2014)
-
A new roadmap for drug development for Alzheimer's disease
Nature Reviews Drug Discovery (2014)
